Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Inhibrx Biosciences, Inc. INBX

Healthcare  —  Biotechnology
99.61 (0.79) (0.79%) as of 25 Sep
Market cap
$1.5B
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Inhibrx Biosciences, Inc. (INBX) Business Profile

Updated before January 2025

Company Overview

Inhibrx Biosciences, Inc. (NASDAQ: INBX) is a clinical-stage biotechnology company dedicated to the development of innovative biologic therapeutics for the treatment of cancer and other serious diseases. Founded in 2010 and headquartered in La Jolla, California, Inhibrx leverages its proprietary protein engineering platform to design and develop therapeutic candidates with high specificity and efficacy. The company was founded by Mark Lappe, who also serves as the Chief Executive Officer. Under his leadership, Inhibrx has grown into a prominent player in the biotechnology sector, with a focus on addressing unmet medical needs through cutting-edge science and technology.

The company’s leadership team includes experienced professionals with extensive backgrounds in biotechnology, pharmaceuticals, and healthcare. Key members of the leadership team include Brendan Eckelman, Ph.D., who serves as the Chief Scientific Officer, and Kelly Deck, the Chief Financial Officer. Together, they guide the company’s strategic direction and oversee its research, development, and commercialization efforts.

Core Business Segments

Inhibrx’s core business revolves around the development of biologic therapeutics, with a primary focus on oncology, rare diseases, and infectious diseases. The company’s product pipeline is built on its proprietary single-domain antibody (sdAb) platform, which enables the creation of highly specific and potent therapeutic candidates. Below are the major product categories and key offerings:

Oncology

Inhibrx is actively developing therapeutic candidates targeting various forms of cancer. Its lead oncology candidate, INBRX-109, is a tetravalent death receptor 5 (DR5) agonist designed to selectively induce apoptosis in cancer cells. INBRX-109 is currently in clinical trials for the treatment of solid tumors, including sarcomas and mesothelioma.

Rare Diseases

The company is also focused on addressing rare diseases with high unmet medical needs. INBRX-101, a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein, is being developed for the treatment of alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder that affects lung and liver function. INBRX-101 is designed to provide sustained therapeutic levels of AAT, potentially improving patient outcomes.

Infectious Diseases

Inhibrx’s pipeline includes candidates targeting infectious diseases, leveraging its sdAb platform to develop therapeutics with high specificity and efficacy. While this segment is still in the early stages of development, it represents a promising area of growth for the company.

Business Model

Inhibrx operates as a clinical-stage biotechnology company, focusing on the research, development, and commercialization of biologic therapeutics. The company’s business model is centered around its proprietary sdAb platform, which enables the design and development of therapeutic candidates with unique properties. By leveraging this platform, Inhibrx aims to address unmet medical needs in oncology, rare diseases, and infectious diseases.

Revenue generation for Inhibrx primarily comes from licensing agreements, collaborations, and milestone payments from partners. As a clinical-stage company, Inhibrx does not yet generate significant revenue from product sales. Instead, it relies on funding from investors, partnerships, and grants to support its research and development activities.

Strategic Direction

Inhibrx’s strategic direction is focused on advancing its pipeline of therapeutic candidates through clinical development and regulatory approval. The company aims to bring innovative treatments to market that address unmet medical needs and improve patient outcomes. Key elements of its strategic plan include:

  • Pipeline Expansion: Inhibrx is committed to expanding its pipeline by leveraging its sdAb platform to develop new therapeutic candidates for oncology, rare diseases, and infectious diseases.
  • Partnerships and Collaborations: The company seeks to establish strategic partnerships with pharmaceutical and biotechnology companies to accelerate the development and commercialization of its products.
  • Sustainability Goals: Inhibrx is dedicated to conducting its operations in an environmentally and socially responsible manner, with a focus on sustainability and ethical practices.
  • Global Reach: The company aims to expand its presence in international markets, ensuring that its therapies are accessible to patients worldwide.

Competitive Landscape

Inhibrx operates in a highly competitive biotechnology sector, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Amgen Inc.: A leading biotechnology company with a strong focus on oncology and biologic therapeutics.
  • Regeneron Pharmaceuticals, Inc.: Known for its innovative biologics and strong pipeline in oncology and rare diseases.
  • Genentech (a member of the Roche Group): A pioneer in biologic therapeutics with a robust oncology portfolio.
  • Sarepta Therapeutics, Inc.: Focused on rare diseases, particularly genetic disorders.
  • Vertex Pharmaceuticals, Inc.: Specializes in therapies for rare diseases, including cystic fibrosis.

Inhibrx differentiates itself through its proprietary sdAb platform, which enables the development of highly specific and potent therapeutic candidates.

Risk Factors

As a clinical-stage biotechnology company, Inhibrx faces several risks, including:

  • Regulatory Risks: The company’s therapeutic candidates must undergo rigorous clinical trials and regulatory approval processes, which can be time-consuming and costly.
  • Market Dependence: Inhibrx’s success depends on the commercial viability of its therapeutic candidates, which are still in development.
  • Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers for the production of its therapeutic candidates, making it vulnerable to supply chain disruptions.
  • Financial Risks: As a pre-revenue company, Inhibrx depends on external funding to support its operations, which may not always be readily available.
  • Competition: The biotechnology sector is highly competitive, with many companies vying for market share in oncology, rare diseases, and infectious diseases.

Recent Developments

Inhibrx has made significant progress in advancing its pipeline of therapeutic candidates. Recent developments include:

  • Clinical Trials: The company has reported positive interim data from its ongoing clinical trials for INBRX-109 and INBRX-101, demonstrating promising efficacy and safety profiles.
  • Regulatory Milestones: Inhibrx has received orphan drug designation for INBRX-101 from the U.S. Food and Drug Administration (FDA), highlighting the potential of this candidate to address a rare disease with high unmet medical needs.
  • Partnerships: The company has entered into strategic collaborations with leading pharmaceutical companies to accelerate the development and commercialization of its therapeutic candidates.

Investment Considerations

Investors considering Inhibrx as a potential investment should weigh the following strengths and risks:

Strengths

  • Proprietary sdAb platform with broad applications in oncology, rare diseases, and infectious diseases.
  • Promising pipeline of therapeutic candidates with strong clinical data.
  • Experienced leadership team with a track record of success in biotechnology.
  • Strategic partnerships and collaborations that provide additional resources and expertise.

Risks

  • Clinical and regulatory risks associated with the development of therapeutic candidates.
  • Dependence on external funding to support operations.
  • Competitive pressures from established pharmaceutical companies and emerging biotech firms.
  • Market risks related to the commercial viability of its products.

Conclusion

Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company with a strong focus on developing innovative biologic therapeutics for oncology, rare diseases, and infectious diseases. Leveraging its proprietary sdAb platform, the company has built a promising pipeline of therapeutic candidates that address unmet medical needs. While Inhibrx faces significant risks as a pre-revenue company, its strong leadership team, strategic partnerships, and innovative approach position it for long-term success. With continued progress in its clinical programs and regulatory milestones, Inhibrx is well-positioned to become a leader in the biotechnology sector, offering significant growth potential for investors.